相关实验视频

Updated: Jan 17, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

当免疫细胞数量升高时,白天服用SHP2抑制剂会缩小神经纤维瘤

Niousha Ahmari¹, Kwangmin Choi¹, Jianqiang Wu¹

¹Divisions of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Life science alliance

|September 24, 2025

概括

通过向单细胞衍生的巨细胞,SHP2抑制会缩小良性神经瘤. 药物的时间是至关重要的,白天给药显示NF1相关的形神经纤维瘤的瘤体积减少.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一个

背景情况:

神经纤维素瘤类型1 (NF1) 通过RAS-MAPK通路的激活引起交叉形神经纤维瘤 (PNFs).
MEK 抑制剂减少PNF大小和与瘤相关的髓状细胞.

研究的目的:

研究SHP2抑制对PNF体积和免疫微环境的影响.
探索SHP2抑制的免疫调节潜力和时间依赖的疗效.

主要方法:

在小鼠模型中利用流细胞计和单细胞RNA测序.
在SHP2抑制后评估瘤体积和免疫细胞种群.

主要成果:

科比美丁尼和SHP2抑制剂RMC-4550都减少了PNF体积.
CD163阴性巨细胞的丰度与瘤大小相关.
抑制SHP2的有效性取决于给药时间 (白天),并通过抗PD1疗法逆转.

结论:

抑制SHP2为PNFs提供了一个潜在的治疗策略.
向单细胞衍生的巨细胞和优化药物给药时间是有效的SHP2抑制剂治疗的关键.

更多相关视频

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.